USA - New York Stock Exchange - NYSE:RDY - US2561352038 - ADR
The current stock price of RDY is 13.28 USD. In the past month the price decreased by -7.17%. In the past year, price decreased by -7.64%.
ChartMill assigns a fundamental rating of 6 / 10 to RDY. RDY scores excellent on profitability, but there are some minor concerns on its financial health.
Over the last trailing twelve months RDY reported a non-GAAP Earnings per Share(EPS) of 0.76. The EPS increased by 8.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.82% | ||
| ROA | 10.62% | ||
| ROE | 16.03% | ||
| Debt/Equity | 0.03 |
45 analysts have analysed RDY and the average price target is 14.92 USD. This implies a price increase of 12.35% is expected in the next year compared to the current price of 13.28.
For the next year, analysts expect an EPS growth of -6.14% and a revenue growth 5.1% for RDY
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 49.05 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 21 | 525.25B | ||
| MRK | MERCK & CO. INC. | 12.61 | 275.78B | ||
| PFE | PFIZER INC | 8.09 | 147.26B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.31 | 110.95B | ||
| ZTS | ZOETIS INC | 19.73 | 55.12B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.66 | 22.93B | ||
| VTRS | VIATRIS INC | 5.6 | 15.03B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.31 | 12.07B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.53B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.55B | ||
| GPCR | STRUCTURE THERAPEUTICS INC | N/A | 5.69B |
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
DR. REDDY'S LABORATORIES-ADR
8-2-337, Road No.3 Banjara Hills
Hyderabad TELANGANA 500-034 IN
CEO: Erez Israeli
Employees: 27048
Phone: 914049002900
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
The current stock price of RDY is 13.28 USD. The price increased by 2.63% in the last trading session.
DR. REDDY'S LABORATORIES-ADR (RDY) has a dividend yield of 0.5%. The yearly dividend amount is currently 0.09.
RDY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
The PE ratio for DR. REDDY'S LABORATORIES-ADR (RDY) is 17.47. This is based on the reported non-GAAP earnings per share of 0.76 and the current share price of 13.28 USD.
DR. REDDY'S LABORATORIES-ADR (RDY) will report earnings on 2026-01-21.
The outstanding short interest for DR. REDDY'S LABORATORIES-ADR (RDY) is 2.1% of its float.